- Home
- CELH vs PCVX Comparison
CELH vs PCVX Comparison
Compare CELH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | PCVX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.0B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CELH | PCVX |
|---|---|---|
| Price | $28.49 | $57.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | $64.81 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 7.0M | 1.1M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $1,318,014,000.00 | N/A |
| Revenue This Year | $37.04 | N/A |
| Revenue Next Year | $9.89 | N/A |
| P/E Ratio | $60.30 | ★ N/A |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $23.56 | $31.51 |
| 52 Week High | $66.74 | $65.00 |
Technical Indicators
Market Signals| Indicator | CELH | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 41.97 |
| Support Level | $27.23 | $52.18 |
| Resistance Level | $30.20 | $58.77 |
| Average True Range (ATR) | 1.08 | 2.07 |
| MACD | -0.32 | -0.41 |
| Stochastic Oscillator | 29.25 | 5.94 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.